Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - immunologicals for aves - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

Δανία - Δανικά - Lægemiddelstyrelsen (Danish Medicines Agency)

ceva-phylaxia co. ltd. - aviær infektiøs bronkitisvirus, stamme massachusetts b-48, frysetørret (levende) - lyofilisat til okulonasal suspension - fjerkræ

Δανία - Δανικά - Lægemiddelstyrelsen (Danish Medicines Agency)

ceva-phylaxia co. ltd. - kalkunherpesvirus, stamme fc 126 (levende, svækket) - suspension og solvens til injektionsvæske, suspension - 2000-8000 pfu - fjerkræ

Δανία - Δανικά - Lægemiddelstyrelsen (Danish Medicines Agency)

ceva-phylaxia co. ltd. - kyllingeherpesvirus, stamme cvi-988 (rispens), levende - koncentrat og solvens til injektionsvæske, suspension

Δανία - Δανικά - Lægemiddelstyrelsen (Danish Medicines Agency)

ceva-phylaxia co. ltd. - aviær metapneumovirus subtype b, stamme crr126 (levende, attenueret) - lyofilisat til okulonasal suspension - fjerkræ

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

ceva santé animale - inaktiverede influenza-a-virus / svin - immunologiske - svin - aktiv immunisering af svin fra 56-års alderen, herunder gravide søer mod svineinfluenza forårsaget af subtype h1n1, h3n2 og h1n2 for at reducere kliniske tegn og viral lungelast efter infektion.. starten af immunitet: 7 dage efter den primære vaccinationduration af immunitet: 4 måneder i svin vaccineret mellem alder af 56 år, og 96 dage og 6 måneder i svin vaccineret for første gang ved 96 dage, og over. aktiv immunisering af gravide søer efter færdig primær immunisering ved indgift af en enkeltdosis 14 dage før farvning for at udvikle høj colostral immunitet, som giver klinisk beskyttelse af smågrise i mindst 33 dage efter fødslen.

Δανία - Δανικά - Lægemiddelstyrelsen (Danish Medicines Agency)

ceva-phylaxia co. ltd. - aviær infektiøs bursitis disease virus, stammevmg 91 (levende) - koncentrat og solvens til injektionsvæske, suspension

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

ceva santé animale - influenza a virus/human strain: a/jena/vi5258/2009 (h1n1)pdm09, inactivated - immunologier, inaktiverede virale vacciner til svin, svineinfluenzavirus - svin - aktiv immunisering af svin fra 8 uger frem mod pandemisk h1n1 svineinfluenzavirus for at reducere viral lungelast og viral udskillelse. the vaccine can be used during pregnancy up to three weeks before expected farrowing and during lactation lactation.

Δανία - Δανικά - Lægemiddelstyrelsen (Danish Medicines Agency)

ceva-phylaxia co. ltd. - aviær infektiøs bursitis virus, stamme syza-26 (levende, svækket), hønsekød - koncentrat og solvens til injektionsvæske, suspension

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - svin - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.